Page 5 - Confidence Interval News Today

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description We begin with a discussion about our article of the week entitled “Electronic nicotine delivery

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...

Less than 2 months after being the subject of an FDA AdComm meeting, Abbott's TriClip TEER System has received approval for tricuspid regurgitation.

A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).

Study links childhood amblyopia with increased risk of cardiometabolic dysfunction in adulthood.

1. In this randomized controlled trial, baricitinib, a Janus kinase (JAK) inhibitor, preserved beta cell function and reduced insulin requirement compared to placebo in patients with new-onset type 1 diabetes mellitus (T1DM). 2. Patients receiving baricitinib also demonstrated tighter glycemic control compared to those receiving the placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia TARRYTOWN, N.Y., March 11, 2024 -- Regeneron Pharmaceuticals, Inc. announced the...

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)...

1. In this randomized controlled trial, tenecteplase administered at 4.5 to 24 hours after stroke onset to patients with an occluded middle cerebral artery (MCA) or internal carotid artery (ICA) was not superior to placebo. 2. Tenecteplase did not differ from placebo with regards to rates of death and symptomatic intracranial hemorrhage. Evidence Rating Level:

1. In this randomized controlled trial, among patients with primary biliary cholangitis (PBC) who had had inadequate response to ursodeoxycholic acid, seladelpar was superior to placebo in achieving biochemical response and symptomatic management. 2. Seladelpar had an acceptable safety profile, with similar rates of adverse events to a placebo. Evidence Rating Level: 1 (Excellent) Study